Uniqure NV (QURE) was Reiterated by WallachBeth to “Buy” while Lowering the Price Target of the company shares to $ 35 from a previous price target of $60 . WallachBeth advised their investors in a research report released on Jun 15, 2016.
Many Wall Street Analysts have commented on Uniqure NV. Shares were Reiterated by WallachBeth on Jun 15, 2016 to “Buy” and Lowered the Price Target to $ 35 from a previous price target of $60 .
Uniqure NV closed down -0.59 points or -5.95% at $9.32 with 11,84,674 shares getting traded on Tuesday. Post opening the session at $9.81, the shares hit an intraday low of $8.735 and an intraday high of $10.1 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration. The Companys first product is Glybera for the treatment of lipoprotein lipase deficiency (LPLD). In the clinical pipeline it has gene treatments for hemophilia porphyria Parkinson Sanfilippo B syndrome and hearing loss. Additionally it is engaged in the development of therapies based on adeno-associated virus (AAV) through multiple collaborations. The Company uses modular technology platform including a cost effective manufacturing process. In August 2014 Uniqure NV acquired InoCard GmbH an early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.